title: Panel discussion. II: Objectives of basic research and predictive value preclinical testing.
authors.affiliation: Bayer AG Health Care Sector R & D, Wuppertal.
authors.forename: F
authors.initials: F
authors.lastname: Hoffmeister
authors.forename: G
authors.initials: G
authors.lastname: Assmann
authors.forename: G V
authors.initials: GV
authors.lastname: Born
authors.forename: F R
authors.initials: FR
authors.lastname: Bühler
authors.forename: W F
authors.initials: WF
authors.lastname: Caspary
authors.forename: R J
authors.initials: RJ
authors.lastname: Feldmann
authors.forename: W
authors.initials: W
authors.lastname: Siegenthaler
mesh_terms: D004353:Drug Evaluation, Preclinical; D004358:Drug Therapy / Q000639:trends*; D010600:Pharmacology / Q000639:trends*; D011237:Predictive Value of Tests; D012106:Research